Skip to main content
SpringerLink
Log in

Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Atrial fibrillation (AF) is well known as one of the leading causes of stroke and systemic embolism. Anticoagulation therapy is recommended in all patients at moderate-to-high risk of stroke. The vitamin K antagonist warfarin has traditionally been used in these patients but presents challenges in dosing and monitoring in these patients. The oral direct thrombin inhibitor dabigatran etexilate (Pradaxa®; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA) was recently approved for use in the US for preventing stroke and systemic embolism in patients with nonvalvular AF. Clinical trials have shown it to reduce the risk of stroke and systemic embolism when compared with warfarin (goal international normalized ratio [INR] 2–3) with a similar risk for severe bleeding. It can be given twice daily, with the dose adjusted for renal function. It does not have any dietary restrictions, has few drug interactions (except involving permeability [P]-glycoprotein [P-gp] agents), and does not require routine laboratory monitoring. Patients may experience significant dyspepsia with its use. Compared with warfarin there is increased risk for gastrointestinal bleeding and perhaps myocardial infarction. Currently, no reversal agent exists for use in situations of overdose or severe bleeding although some strategies have been suggested. Despite its high acquisition cost compared with warfarin, analysis using theoretical models has shown it to be cost-effective. Dabigatran offers a unique alternative to warfarin in patients with nonvalvular AF and can be beneficial in patients requiring anticoagulation therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Go AS, Hylek EM, Phillips JA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention; the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375.

    Article  PubMed  CAS  Google Scholar 

  2. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:546S–592S.

    Article  PubMed  CAS  Google Scholar 

  3. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995;155:468–473.

    Article  Google Scholar 

  4. Lakshminarayan K, Solid CA, Collins AJ, et al. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002). Stroke. 2006;37:1969–1974.

    Article  PubMed  Google Scholar 

  5. Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167:246–252.

    Article  PubMed  Google Scholar 

  6. [No authors listed.] Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457.

  7. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists. Chest. 2008;133:160S–198S.

    Article  PubMed  CAS  Google Scholar 

  8. Hirsh J, O’Donnell M, Eikelboon JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation. 2007;116:552–560.

    Article  PubMed  CAS  Google Scholar 

  9. Baetz BE, SA Spinler. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy. 2008;28:1354–1373.

    Article  PubMed  CAS  Google Scholar 

  10. Dager WE, Branch JM, King JH, et al. Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service. Ann Pharmacother. 2000;34:567–572.

    Article  PubMed  CAS  Google Scholar 

  11. Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 2004;24:953–963.

    Article  PubMed  CAS  Google Scholar 

  12. Baker WL, Cios DA, Sander SD, et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Managed Care Pharm. 2009;15:245–253.

    Google Scholar 

  13. Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa Medication Guide. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.

  14. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15:9S–16S.

    Article  PubMed  CAS  Google Scholar 

  15. European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (CHMP) assessment report for Pradaxa. 2008. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed April 14, 2011.

  16. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98:155–162.

    PubMed  CAS  Google Scholar 

  17. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285–295.

    Article  PubMed  CAS  Google Scholar 

  18. Di Nisio M, Middeldrorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028–1040.

    Article  PubMed  Google Scholar 

  19. Sanford M, Plosker GL. Dabigatran etexilate. Drugs. 2008;68:1699–1709.

    Article  PubMed  CAS  Google Scholar 

  20. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics, and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303.

    Article  PubMed  CAS  Google Scholar 

  21. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:103–111.

    Article  Google Scholar 

  22. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555–563.

    Article  PubMed  CAS  Google Scholar 

  23. Siddiqui FM, Qureshi AI. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. Expert Opin Pharmacother. 2010;11:1403–1411.

    Article  PubMed  CAS  Google Scholar 

  24. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–399.

    Article  PubMed  CAS  Google Scholar 

  25. Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. An open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259–268.

    Article  PubMed  CAS  Google Scholar 

  26. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48:1411–1419.

    Article  PubMed  CAS  Google Scholar 

  27. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100:1419–1426.

    Article  PubMed  CAS  Google Scholar 

  28. Nagarakanti R, Ezekowitz MD, Parcham-Azad K, et al. Long-term open label extension of the Prevention of Embolic and Thrombotic Events on Dabigatran in Atrial Fibrillation (PETRO-Ex) study. Circulation. 2008;118:S_922. Abstract # 4629.

    Google Scholar 

  29. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805–810.e2.

    Article  PubMed  CAS  Google Scholar 

  30. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.

    Article  PubMed  CAS  Google Scholar 

  31. Deinher HC, Executive Steering Committee of the SPORTIFF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation: pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis. 2006;21:279–293.

    Article  Google Scholar 

  32. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875–1876.

    Article  PubMed  CAS  Google Scholar 

  33. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). J Am Coll Cardiol. 2011;57:1330–1337.

    Article  PubMed  Google Scholar 

  34. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255–1262.

    Google Scholar 

  35. Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack of stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9:1157–1111.

    Article  PubMed  CAS  Google Scholar 

  36. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation. 2011;123:e269–e367.

    Article  PubMed  Google Scholar 

  37. Weinberg DM, Mancini J. Anticoagulation for conversion of atrial fibrillation. Am J Cardiol. 189;63:745–746.

  38. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. An analysis of patients undergoing cardioversion. Circulation. 2011;123:131–136.

    Article  PubMed  CAS  Google Scholar 

  39. Albers GW, Diener HC, Grind M, et al. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003;362:1691–1698.

    Article  Google Scholar 

  40. Albers GW, diener HC, Frison L, et al. Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA. 2005;293:690–698.

    Article  PubMed  Google Scholar 

  41. Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naïve and -experienced cohorts with atrial fibrillation. Circulation. 2010;122:2246–2253.

    Article  PubMed  CAS  Google Scholar 

  42. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–983.

    Article  PubMed  CAS  Google Scholar 

  43. Clemens A, Yamamura N, Rathgen, et al. Switching from enoxaparin to dabigatran etexilate: effects on safety, pharmacokinetics and pharmacodynamics. Pharm World Sci. 2010;32:285. Abstract #PK-06.

    Google Scholar 

  44. Van Ryn J, Sieger P, Kink-eiband M, et al. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. Blood. 2009;114. Abstract# 1065.

    Google Scholar 

  45. Van Ryn J, Ruehl D, Priepke H, et al. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica. 2008;93:148s. Abstract # 0370.

    Google Scholar 

  46. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate — a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–1127.

    Article  PubMed  Google Scholar 

  47. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31:326–343.

    Article  PubMed  CAS  Google Scholar 

  48. Stangier J, Stahle H, Rathgen K, et al. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin. Thromb Haemost. 2007;5. Abstract#P-W_672.

    Google Scholar 

  49. Stangier J, Rathgen K, Stahle H, et al. Coadministration of dabigatran etexilate and atorvastatin. Assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9:59–68.

    PubMed  CAS  Google Scholar 

  50. Freeman JV, Ruo PZ, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1–11.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Schools of Pharmacy and Medicine, Storrs and Farmington CT & Department of Hematology-Oncology, University of Connecticut, 263 Farmington Ave, MC2205, Farmington, CT, 06030, USA

    Stephen D. Bendel, Robert Bona & William L. Baker

Authors
  1. Stephen D. Bendel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Bona
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William L. Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William L. Baker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bendel, S.D., Bona, R. & Baker, W.L. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. Adv Therapy 28, 460–472 (2011). https://doi.org/10.1007/s12325-011-0025-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0025-1

Keywords

Search

Navigation